Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Supramolecular antimicrobial capsules assembled from polyoxometalates and chitosan

  • De Matteis, Laura
  • Mitchell, Scott G.
  • Fuente, Jesús M. de la
This communication describes a surfactant-based strategy towards spherical metal-organic nanohybrid structures with antimicrobial properties. We demonstrate that the growth of the Gram-negative bacterium E.coli can be dramatically affected by the presence of these hybrid materials and that this effect strictly depends on the type of contained polyoxometalate and on the size of the composites., This work has been funded by the Marie Curie Intra-European Fellowship 328985-COCOPOPS, ERC-Starting Grant 239931-NANOPUZZLE and European Seventh Framework Programme (NAREB Project 604237)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Controlling properties and cytotoxicity of chitosan nanocapsules by chemical grafting

  • De Matteis, Laura
  • Alleva, María
  • Serrano-Sevilla, Inés
  • García-Embid, Sonia
  • Stepien, Grazyna
  • Moros, María
  • Fuente, Jesús M. de la
The tunability of the properties of chitosan-based carriers opens new ways for the application of drugs with low water-stability or high adverse effects. In this work, the combination of a nanoemulsion with a chitosan hydrogel coating and the following poly (ethylene glycol) (PEG) grafting is proven to be a promising strategy to obtain a flexible and versatile nanocarrier with an improved stability. Thanks to chitosan amino groups, a new easy and reproducible method to obtain nanocapsule grafting with PEG has been developed in this work, allowing a very good control and tunability of the properties of nanocapsule surface. Two different PEG densities of coverage are studied and the nanocapsule systems obtained are characterized at all steps of the optimization in terms of diameter, Z potential and surface charge (amino group analysis). Results obtained are compatible with a conformation of PEG molecules laying adsorbed on nanoparticle surface after covalent linking through their amino terminal moiety. An improvement in nanocapsule stability in physiological medium is observed with the highest PEG coverage density obtained. Cytotoxicity tests also demonstrate that grafting with PEG is an effective strategy to modulate the cytotoxicity of developed nanocapsules. Such results indicate the suitability of chitosan as protective coating for future studies oriented toward drug delivery., Authors would like to acknowledge the public funding from Fondo Social de la DGA (grupos DGA), Ministerio de la Economía y Competitividad del Gobierno de España for the public founding of ProyectosI+D+i—Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (project n. SAF2014-54763-C2-2-R), the European Seventh Framework Program (NAREB Project 604237), LLP/Erasmus fellowship 2013/2014, INA fellowship “Iniciación a la Investigación” 2014 and 2015, and the European Union’s Horizon 2020 research and innovation program for MCSA Fellowship (Grant Agreement No. 660228)., We acknowledge support by the CSIC Open Access Publication Initiative through its Unit of Information Resources for Research (URICI).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

New active formulations against M. tuberculosis: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules

  • De Matteis, Laura
  • Jary, Dorothée
  • Lucía, Ainhoa
  • García-Embid, Sonia
  • Serrano-Sevilla, Inés
  • Pérez, Daniel
  • Aínsa, José A.
  • Navarro, Fabrice
  • Fuente, Jesús M. de la
In the last years, the increase in antimicrobial resistance, together with a lack of new drugs for the treatment of bacterial infections resistant to classical antibiotics are of growing concern. Moreover, some of current therapies induce severe side effects and are often difficult to administer. In 2012 the FDA approved the use of bedaquiline, as the first new very effective drug against TB in the last 40 years. Despite its effectiveness, unfortunately bedaquiline side effects can be so dangerous that at present it is to be prescribed only when no other treatment options are available. The development of effective and safe nanotechnology-based methods can be particularly relevant to increase antimicrobial concentration at the site of infection, to reduce doses in the general circulation, which in turn reduces adverse effects. In this work bedaquiline was encapsulated in two types of nanocarriers, lipid nanoparticles and chitosan-based nanocapsules with high encapsulation efficiency and drug loading values. The efficacy of the drug-encapsulating nanocarriers has been demonstrated in vitro against Mycobacterium tuberculosis, together with the excellent compatibility of both carriers with animal cells. The obtained results open the way for further studies on multi-drug resistant strains of M. tuberculosis and for in vivo studies of the optimized nanocarriers. The promising behaviour of drug-loaded nanocarriers will hopefully lead to a reduction of the administered doses of a quite dangerous drug as bedaquiline, tuning its biodistribution and so decreasing its adverse effects, finally allowing its use in a higher number of patients., Authors would like to acknowledge the public funding from Fondo Social de la DGA (grupos DGA), Ministerio de la Economía y Competitividad del Gobierno de España for the public founding of ProyectosI + D + i – ProgramaEstatal de Investigación, Desarrollo e InnovaciónOrientada a los Retos de la Sociedad (project n. SAF2014-54763-C2-2-R), the European Seventh Framework Program (NAREB Project 604237) and Ministerio de Educación Cultura y Deporte for SGE fellowship., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Tri-mannose grafting of chitosan nanocarriers remodels the macrophage response to bacterial infection

  • Coya, Juan Manuel
  • De Matteis, Laura
  • Giraud-Gatineau, Alexandre
  • Biton, Anne
  • Serrano-Sevilla, Inés
  • Danckaert, Anne
  • Dillies, Marie-Agnès
  • Gicquel, Brigitte
  • Fuente, Jesús M. de la
  • Tailleux, Ludovic
[Background]: Infectious diseases are still a leading cause of death and, with the emergence of drug resistance, pose a great threat to human health. New drugs and strategies are thus urgently needed to improve treatment efficacy and limit drug-associated side effects. Nanotechnology-based drug delivery systems are promising approaches, offering hope in the fight against drug resistant bacteria. However, how nanocarriers influence the response of innate immune cells to bacterial infection is mostly unknown., [Results]: Here, we used Mycobacterium tuberculosis as a model of bacterial infection to examine the impact of mannose functionalization of chitosan nanocarriers (CS-NCs) on the human macrophage response. Both ungrafted and grafted CS-NCs were similarly internalized by macrophages, via an actin cytoskeleton-dependent process. Although tri-mannose ligands did not modify the capacity of CS-NCs to escape lysosomal degradation, they profoundly remodeled the response of M. tuberculosis-infected macrophages. mRNA sequencing showed nearly 900 genes to be differentially expressed due to tri-mannose grafting. Unexpectedly, the set of modulated genes was enriched for pathways involved in cell metabolism, particularly oxidative phosphorylation and sugar metabolism., [Conclusions]: The ability to modulate cell metabolism by grafting ligands at the surface of nanoparticles may thus be a promising strategy to reprogram immune cells and improve the efficacy of encapsulated drugs., This research project was co-financed by the Institut Pasteur and the European Commission as part of the European Seventh Framework Program Nanotherapeutics against Resistant Emerging Bacterial Pathogens (NAREB Project 604237), public funding from the Fondo Social de la DGA (grupos DGA), Ministerio de Economía y Competitividad del Gobierno de España for the public founding of the Proyectos I+D+I—Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Polysaccharide-coated polypeptidic micelles for drug delivery

  • Soria-Carrera, Héctor
  • De Matteis, Laura
  • Lucía, Ainhoa
  • Aínsa, José A.
  • Martín-Rapún, Rafael
  • Fuente, Jesús M. de la
Resumen del trabajo presentado a la Self-Assembly of Colloïdal Systems (SACS), celebrada en Bordeaux (Francia) del 20 al 22 de septiembre de 2018., Polypeptides and block copolypeptides prepared by ring opening polymerization of Ncaboxyanhydrides of protected aminoacids have attracted great research interest due to their broad structural and chemical diversity, their self-assembling properties and their intrinsic biocompatibility. In this contribution we present a carrier for drug delivery based on micelles formed by block copolypeptides of benzyloxycarbonyl lysine and glutamic acid. Upon tuning of the structure, highly reproducible and homogeneous micelles can be produced. We have improved the stability of the system by coating the particles with polysaccharides. Our methodology has permitted the encapsulation of a hydrophobic antimicrobial drug, which reinforces the micelle formation. Drug release experiments reveal an improved performance for coated micelles in different media and indicate the system might be appropriate for oral drug delivery. Our studies with M. tuberculosis bacteria in vitro show a promising decrease in the minimum inhibitory concentration compared to the controls., This work has been funded by Ministerio de Economía y Competitividad (Spain) (project CTQ2015-66869-P and RYC-2013-12570), the European Seventh Framework Program (NAREB Project 604237) and Ministerio de Educación Cultura y Deporte (Spain) (FPU fellowship of HSC)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Co-delivery of free vancomycin and transcription factor decoy-nanostructured lipid carriers can enhance inhibition of methicillin resistant Staphylococcus aureus (MRSA)

  • Hibbitts, Alan
  • Lucía, Ainhoa
  • Serrano-Sevilla, Inés
  • De Matteis, Laura
  • McArthur, Michael
  • Fuente, Jesús M. de la
  • Aínsa, José A.
  • Navarro, Fabrice
Bacterial resistance to antibiotics is widely regarded as a major public health concern with last resort MRSA treatments like vancomycin now encountering resistant strains. TFDs (Transcription Factor Decoys) are oligonucleotide copies of the DNA-binding sites for transcription factors. They bind to and sequester the targeted transcription factor, thus inhibiting transcription of many genes. By developing TFDs with sequences aimed at inhibiting transcription factors controlling the expression of highly conserved bacterial cell wall proteins, TFDs present as a potential method for inhibiting microbial growth without encountering typical resistance mechanisms. However, the efficient protection and delivery of the TFDs inside the bacterial cells is a critical step for the success of this technology. Therefore, in our study, specific TFDs against S. aureus were complexed with two different types of nanocarriers: cationic nanostructured lipid carriers (cNLCs) and chitosan-based nanoparticles (CS-NCs). These TFD-carrier nanocomplexes were characterized for size, zeta potential and TFD complexation or loading efficiency in a variety of buffers. In vitro activity of the nanocomplexes was examined alone and in combination with vancomycin, first in methicillin susceptible strains of S. aureus with the lead candidate advancing to tests against MRSA cultures. Results found that both cNLCs and chitosan-based carriers were adept at complexing and protecting TFDs in a range of physiological and microbiological buffers up to 72 hours. From initial testing, chitosan-TFD particles demonstrated no visible improvements in effect when co-administered with vancomycin. However, co-delivery of cNLC-TFD with vancomycin reduced the MIC of vancomycin by over 50% in MSSA and resulted in significant decreases in viability compared with vancomycin alone in MRSA cultures. Furthermore, these TFD-loaded particles demonstrated very low levels of cytotoxicity and haemolysis in vitro. To our knowledge, this is the first attempt at a combined antibiotic/oligonucleotide-TFD approach to combatting MRSA and, as such, highlights a new avenue of MRSA treatment combining traditional small molecules drugs and bacterial gene inhibition., This work was undertaken as part of the Nano-therapeutics for Antibiotic Resistant Emerging Bacterial Pathogens (NAREB) European research network supported by the EU FP7 under grant agreement 604237. JMF, LM and ISS thank the financial support from the Ministerio de Ciencia, Innovación y Universidades (BIO2017-84246-C2-1-R) and Gobierno de Aragón and Fondos Feder (Bionanosurf E15_17R). ISS acknowledges Ministerio de Economía y Competitividad del Gobierno de España for her FPI grant (BES-2015-071304). JAA ackowledges funding from the Ministerio de Ciencia, Innovación y Universidades (SAF2017-84839-C2-2-R) and Gobierno de Aragón and Fondos Feder (Grupo de Genética de Micobacterias B35 17R)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

New active formulations against M. tuberculosis: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules

  • De Matteis, Laura
  • Jary, Dorothée
  • Lucia Quintana, Ainhoa
  • García-Embid, Sonia
  • Serrano-Sevilla, Inés
  • Pérez, Daniel
  • Aínsa Claver, Jose Antonio
  • Navarro, Fabrice
  • Martínez De la Fuente, Jesús
In the last years, the increase in antimicrobial resistance, together with a lack of new drugs for the treatment of bacterial infections resistant to classical antibiotics are of growing concern. Moreover, some of current therapies induce severe side effects and are often difficult to administer. In 2012 the FDA approved the use of bedaquiline, as the first new very effective drug against TB in the last 40¿years. Despite its effectiveness, unfortunately bedaquiline side effects can be so dangerous that at present it is to be prescribed only when no other treatment options are available. The development of effective and safe nanotechnology-based methods can be particularly relevant to increase antimicrobial concentration at the site of infection, to reduce doses in the general circulation, which in turn reduces adverse effects. In this work bedaquiline was encapsulated in two types of nanocarriers, lipid nanoparticles and chitosan-based nanocapsules with high encapsulation efficiency and drug loading values. The efficacy of the drug-encapsulating nanocarriers has been demonstrated in vitro against Mycobacterium tuberculosis, together with the excellent compatibility of both carriers with animal cells. The obtained results open the way for further studies on multi-drug resistant strains of M. tuberculosis and for in vivo studies of the optimized nanocarriers. The promising behaviour of drug-loaded nanocarriers will hopefully lead to a reduction of the administered doses of a quite dangerous drug as bedaquiline, tuning its biodistribution and so decreasing its adverse effects, finally allowing its use in a higher number of patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Tri-mannose grafting of chitosan nanocarriers remodels the macrophage response to bacterial infection

  • Coya, J.M.
  • De Matteis, L.
  • Giraud-Gatineau, A.
  • Biton, A.
  • Serrano-Sevilla, I.
  • Danckaert, A.
  • Dillies, M.A.
  • Gicquel, B.
  • De La Fuente, J.M.
  • Tailleux, L.
Background: Infectious diseases are still a leading cause of death and, with the emergence of drug resistance, pose a great threat to human health. New drugs and strategies are thus urgently needed to improve treatment efficacy and limit drug-associated side effects. Nanotechnology-based drug delivery systems are promising approaches, offering hope in the fight against drug resistant bacteria. However, how nanocarriers influence the response of innate immune cells to bacterial infection is mostly unknown. Results: Here, we used Mycobacterium tuberculosis as a model of bacterial infection to examine the impact of mannose functionalization of chitosan nanocarriers (CS-NCs) on the human macrophage response. Both ungrafted and grafted CS-NCs were similarly internalized by macrophages, via an actin cytoskeleton-dependent process. Although tri-mannose ligands did not modify the capacity of CS-NCs to escape lysosomal degradation, they profoundly remodeled the response of M. tuberculosis-infected macrophages. mRNA sequencing showed nearly 900 genes to be differentially expressed due to tri-mannose grafting. Unexpectedly, the set of modulated genes was enriched for pathways involved in cell metabolism, particularly oxidative phosphorylation and sugar metabolism. Conclusions: The ability to modulate cell metabolism by grafting ligands at the surface of nanoparticles may thus be a promising strategy to reprogram immune cells and improve the efficacy of encapsulated drugs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Co-delivery of free vancomycin and transcription factor decoy-nanostructured lipid carriers can enhance inhibition of methicillin resistant Staphylococcus aureus (MRSA)

  • Hibbitts, Alan
  • Lucía, Ainhoa
  • Serrano-Sevilla, Inés
  • De Matteis, Laura
  • McArthur, Michael
  • De La Fuente, Jesús M.
  • Aínsa, José A.
  • Navarro, Fabrice
Bacterial resistance to antibiotics is widely regarded as a major public health concern with last resort MRSA treatments like vancomycin now encountering resistant strains. TFDs (Transcription Factor Decoys) are oligonucleotide copies of the DNA-binding sites for transcription factors. They bind to and sequester the targeted transcription factor, thus inhibiting transcription of many genes. By developing TFDs with sequences aimed at inhibiting transcription factors controlling the expression of highly conserved bacterial cell wall proteins, TFDs present as a potential method for inhibiting microbial growth without encountering typical resistance mechanisms. However, the efficient protection and delivery of the TFDs inside the bacterial cells is a critical step for the success of this technology. Therefore, in our study, specific TFDs against S. aureus were complexed with two different types of nanocarriers: cationic nanostructured lipid carriers (cNLCs) and chitosan-based nanoparticles (CSNCs). These TFD-carrier nanocomplexes were characterized for size, zeta potential and TFD complexation or loading efficiency in a variety of buffers. In vitro activity of the nanocomplexes was examined alone and in combination with vancomycin, first in methicillin susceptible strains of S. aureus with the lead candidate advancing to tests against MRSA cultures. Results found that both cNLCs and chitosan-based carriers were adept at complexing and protecting TFDs in a range of physiological and microbiological buffers up to 72 hours. From initial testing, chitosan-TFD particles demonstrated no visible improvements in effect when co-administered with vancomycin. However, co-delivery of cNLC-TFD with vancomycin reduced the MIC of vancomycin by over 50% in MSSA and resulted in significant decreases in viability compared with vancomycin alone in MRSA cultures. Furthermore, these TFD-loaded particles demonstrated very low levels of cytotoxicity and haemolysis in vitro. To our knowledge, this is the first attempt at a combined antibiotic/oligonucleotide-TFD approach to combatting MRSA and, as such, highlights a new avenue of MRSA treatment combining traditional small molecules drugs and bacterial gene inhibition. © 2019 Hibbitts et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Bedaquiline loaded lipid nanoparticles: a promising candidate for TB treatment

  • D. Jary
  • A. Hibbits
  • T. Lozano-Fernández
  • D. Pérez
  • A. Lucía
  • J.A. Aínsa
  • N. Redinger
  • U. E. Schaible
  • J.M. Coya Raboso
  • L. Tailleux
  • B. Gicquel
  • F. Navarro
Four different kinds of Lipid Nanoparticles (LNP) encapsulating bedaquiline have been tested in order to evaluate the possibility to decrease adverse effects of this very efficient and recent antibiotic. The parameters that are studied among these different types of LNP are the surface charge as well as targeting of macrophages through trimannose groups grafted to the surface. It was found that these nanocarriers could encapsulate bedaquiline with a very high loading efficiency, exhibited a very good colloidal stability in storage conditions as well as in biological media, and an excellent compatibility with animal cells. Finally, first in vivo evaluation showed that these carriers are able to accumulate strongly in the lungs and that the almost neutral ones without targeting ligands could be the best candidate for tuberculosis treatment.